The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AADi; AstraZeneca/MedImmune; Bayer; Elevar Therapeutics; Regeneron; Totus Medicines; TransThera Sciences (Nanjing), Inc.; Valar Labs
Speakers' Bureau - AstraZeneca; Incyte; Seagen
Research Funding - Ability Pharma (Inst); Amgen (Inst); Apexigen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bexion (Inst); Bristol-Myers Squibb (Inst); FibroGen (Inst); Genentech (Inst); Hengrui Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); NextCure (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Triumvira Immunologics, Inc (Inst)
Travel, Accommodations, Expenses - Ability Pharma
A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.
 
Neil Howard Segal
Consulting or Advisory Role - Agenus; AstraZeneca; Novartis; Numab; PureTech; regeneron
Research Funding - Agenus (Inst); AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer; PureTech (Inst); Regeneron (Inst); Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Regeneron
 
Eugenia Girda
Consulting or Advisory Role - Merck
 
Davendra Sohal
No Relationships to Disclose
 
Nehal J. Lakhani
Research Funding - Alexo Therapeutics (Inst); Alkermes (Inst); Alkermes/Mural Oncology (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Arcus Ventures (Inst); Artios (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech SE (Inst); Biosplice (Inst); Celgene (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Janssen (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Instil Bio; Merck; Novartis; Oncosec; Pfizer; Replimune
Research Funding - Alkermes (Inst); Antengene (Inst); Antengene (Inst); Eutilex (Inst); F-Star Biotechnology (Inst); GlaxoSmithKline (Inst); HiFiBiO Therapeutics (Inst); Kadmon (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); Lantern Pharma (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Shionogi (Inst); Sumitomo Group (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Takeda
 
Lawrence Fong
Stock and Other Ownership Interests - Actym Therapeutics; Alector; Atreca; BioAtla; Bolt Biotherapeutics; ImmunoGenesis; NGM Biopharmaceuticals; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Senti Biosciences; Sutro Biopharma
Consulting or Advisory Role - Actym Therapeutics; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Dendreon; EMD Serono; ImmunoGenesis; Innovent Biologics; Janssen Oncology; Merck; NGM Biopharmaceuticals; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Roche/Genentech
Research Funding - Abbvie (Inst); Amgen (Inst); Bavarian Nordic (Inst); Dendreon (Inst); Merck (Inst)
 
Michael David Kinnaman
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Consulting or Advisory Role - Cardinal Health
 
Hyunsil Han
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Kerry A. Casey
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
JuAn Wang
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Yi Hao
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Siyu Li
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Samit Ganguly
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Frank A. Seebach
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Melissa Divya Mathias
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Alentis Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Hookipa Biotech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Molecular Axiom (Inst); Normunity (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Revolution Medicines (Inst); Sanofi (Inst); SeaGen (Inst); Synthekine (Inst); Takeda (Inst); VBL Therapeutics (Inst)
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); ArriVent Biopharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); Bayer (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Checkpoint Therapeutics (Inst); City of Hope (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunitas (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Taiho Oncology (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); WindMIL (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi